Plagiocephaly Device First To Avoid Class III Status Via FDAMA Provision
This article was originally published in The Gray Sheet
Executive Summary
Cranial orthosis devices intended to treat severe non-synostotic positional plagiocephaly in infants three to 18 months of age are the first generic device type to avoid default Class III status via Sec. 207 of the FDA Modernization Act.
You may also be interested in...
VGI Trugene HIV-1 Test Downclassification Petition Anticipated By August
Visible Genetics, Inc. plans to submit a petition to FDA by August seeking classification of its Trugene HIV-1 genotyping test and OpenGene DNA sequencing system as Class II following FDA's rejection of a September 2000 510(k) submission.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.